← Oncology Approval Tracker

FDA DECISION ·

Tibsovo + azacitidine

ivosidenib plus azacitidine · Servier

FDA approvalNew or expanded indicationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed AML and a susceptible IDH1 mutation identified by an FDA-approved test, age 75 or older or with comorbidities precluding intensive induction chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The combination introduces an IDH1-directed option for newly diagnosed patients unsuited to intensive induction.

What research teams should watch

Confirm IDH1 testing and the basis for induction ineligibility. Plan escalation for differentiation syndrome.

PRIMARY RECORDS

Sources